Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Plus components not separately reported this period.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
FAQ
- What is Neurocrine Biosciences's EBIT?
- Neurocrine Biosciences (NBIX) reported EBIT of $193.4M in Q1 2026.
- How has Neurocrine Biosciences's EBIT changed year-over-year?
- Neurocrine Biosciences's EBIT increased by 719.5% year-over-year, from $23.6M to $193.4M.
- What is the long-term trend for Neurocrine Biosciences's EBIT?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's EBIT has grown at a 35.5% compound annual growth rate (CAGR), from $249M to $619.1M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Neurocrine Biosciences's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude